

United States Patent and Trademark Office

KJ

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/840,085	04/24/2001	Alanna Schepartz Shrader	YU-P01-021	2186
28120	7590 06/01/2006		EXAMINER	
FISH & NE	AVE IP GROUP	ALLEN, MARIANNE P		
ROPES & GRAY LLP				
ONE INTERNATIONAL PLACE			ART UNIT	PAPER NUMBER
BOSTON, MA 02110-2624			1647	
			DATE MAILED: 06/01/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

 		Application No.	Applicant(s)			
Office Action Summary						
		09/840,085	SHRADER ET AL.			
	Onice Action Summary	Examiner	Art Unit			
		Marianne P. Allen	1647			
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
WHIC - Exter after - If NO - Failu Any r	ORTENED STATUTORY PERIOD FOR REP CHEVER IS LONGER, FROM THE MAILING asions of time may be available under the provisions of 37 CFR of SIX (6) MONTHS from the mailing date of this communication. The period for reply is specified above, the maximum statutory period are to reply within the set or extended period for reply will, by state eply received by the Office later than three months after the mail and patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 1.136(a). In no event, however, may a reply be tird d will apply and will expire SIX (6) MONTHS from the, cause the application to become ABANDONE	N. mely filed the mailing date of this communication. ED (35 U.S.C. § 133).			
Status						
1)⊠	Responsive to communication(s) filed on 15	March 2006				
	Responsive to communication(s) filed on <u>15 March 2006</u> . This action is FINAL . 2b) This action is non-final.					
	,—					
3)	, proceedings of the state of t					
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Dispositi	on of Claims					
4)⊠	Claim(s) <u>1-5 and 12-27</u> is/are pending in the application.					
•	4a) Of the above claim(s) <u>14-18 and 20-22</u> is/are withdrawn from consideration.					
	5) Claim(s) is/are allowed.					
6)⊠	6)⊠ Claim(s) <u>1-5, 12-13, 19, 23-27</u> is/are rejected.					
	☐ Claim(s) is/are objected to.					
	Claim(s) <u>1-5 and 12-27</u> are subject to restrict	ion and/or election requirement.				
· · _	on Papers					
9) The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
	Applicant may not request that any objection to the					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority u	ınder 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment	`'					
2) 🔲 Notice 3) 🔯 Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/0 r No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:				

DETAILED ACTION

Claims 1-5, 12-13, 19, and 23-27 are under consideration by the examiner.

Applicant is advised that the examiner has examined the claims with respect to SEQ ID NOS. 23-29. No other sequences are under consideration and the claims have only been examined to the degree that they reflect SEQ ID NOS: 23-29.

Applicant's arguments filed 3/15/06 have been fully considered but they are not persuasive.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Election/Restrictions

This application contains claims 14-18 and 20-22 drawn to a nonelected invention. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

Claim Rejections - 35 USC § 112

Claims 1-5, 12-13, 19, and 23-27 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for SEQ ID NOS: 23-29 does not reasonably provide enablement for avian pancreatic polypeptides with the stated substitutions and properties. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

This rejection is maintained for reasons of record.

Application/Control Number: 09/840,085

Art Unit: 1647

Page 3

Applicant argues at page 9 of the response that "one of skill in the art would readily understand that the term 'avian pancreatic polypeptide' means the unique aPP protein." This assertion is not supported by any evidence nor is it agreed with by the examiner. There is no limiting definition in the specification for this phrase as being a particular protein and thus one of ordinary skill in the art must interpret the claim using the plain meaning of the words. The plain meaning of the phrase is any polypeptide found in a pancreatic tissue from an avian species.

Applicant is reminded that during examination the claims are given their broadest reasonable interpretation. This means that the words of the claim must be given their plain meaning unless applicant has provided a clear definition in the specification. In re Zletz, 893 F.2d 319, 321, 13 USPQ2d 1320, 1322 (Fed. Cir. 1989); Chef America, Inc. v. Lamb-Weston, Inc., 358 F.3d 1371, 1372, 69 USPQ2d 1857 (Fed. Cir. 2004). Ordinary, simple English words whose meaning is clear and unquestionable, absent any indication that their use in a particular context changes their meaning, are construed to mean exactly what they say.

Applicant's arguments with respect to page 38 and peptides of SEQ ID NOS: 27, 28, and 29 binding Bcl are not persuasive. This section does not make clear that these particular peptides bind and Figure 4 provides no Kd for them.

Applicant's response does not identify where within SEQ ID NO: 6 the sequences represented by SEQ ID NOS: 23-29 are present.

The claims remain an invitation to experiment and would constitute undue experimentation in view of the lack of guidance and unpredictability in the art.

Application/Control Number: 09/840,085

Art Unit: 1647

Page 4

Claim Rejections - 35 USC § 102

Claims 1-5, 12-13, 23, 24, and 25 are rejected under 35 U.S.C. 102(b) as being anticipated by Chittenden et al. (U.S. Patent No. 5,656,725).

This rejection is maintained for reasons of record.

As set forth above, there is no limiting definition in the specification for the phrase "avain pancreatic polypeptide" as being a particular protein and thus one of ordinary skill in the art must interpret the claim using the plain meaning of the words. The plain meaning of the phrase is any polypeptide found in a pancreatic tissue from an avian species. Applicant is reminded that during examination the claims are given their broadest reasonable interpretation. This means that the words of the claim must be given their plain meaning unless applicant has provided a clear definition in the specification. In re Zletz, 893 F.2d 319, 321, 13 USPQ2d 1320, 1322 (Fed. Cir. 1989); Chef America, Inc. v. Lamb-Weston, Inc., 358 F.3d 1371, 1372, 69 USPQ2d 1857 (Fed. Cir. 2004). Ordinary, simple English words whose meaning is clear and unquestionable, absent any indication that their use in a particular context changes their meaning, are construed to mean exactly what they say.

Claim Rejections - 35 USC § 103

Claims 1-5, 12-13, and 23-25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Zondlo et al. (J. Am. Chem. Soc., 121:6938-939, 1999) in view of Sattler et al. (Science, 275:983-986, 1997).

This rejection is maintained for reasons of record and as discussed above with respect to the meaning of "avian pancreatic polypeptide."

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Marianne P. Allen whose telephone number is 571-272-0712. The examiner can normally be reached on Monday-Thursday, 5:30 am - 1:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached on 571-272-0961. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent
Application Information Retrieval (PAIR) system. Status information for published applications
may be obtained from either Private PAIR or Public PAIR. Status information for unpublished
applications is available through Private PAIR only. For more information about the PAIR

Art Unit: 1647

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Marianne P. Allen
Primary Examiner
Art Unit 1647

mpa